布鲁克收购 Bridge12 的电子顺磁共振（EPR）业务
ZUERICH, Switzerland – October 7th, 2024: Bruker BioSpin Group today announced the acquisition of the Electron Paramagnetic Resonance (EPR) business of Bridge12, a Massachusetts-based company (www.bridge12.com). With Bridge12’s solutions for certain cutting-edge research using EPR technology, Bruker further enhances its suite of EPR spectroscopy offerings.
Bridge12 offers modular EPR bridges for pulsed spectroscopy, high-field EPR spectrometers for multi-frequency experiments, microwave amplifiers, and EPR probes. Their innovative technology and collaborative research initiatives aim to advance EPR spectroscopy, providing superior versatility in EPR instrumentation.
Dr. Thorsten Maly, co-founder and VP of Magnetic Resonance at Bridge12, stated: “Joining Bruker represents a major step for our advanced EPR technology. It allows us to scale our innovations and make them accessible to a broad research community, ensuring long-term, global support and driving sustainability in innovation. I look forward to collaborating with more leading scientists to apply EPR spectroscopy in new ways.”
Dr. Falko Busse, President of the Bruker BioSpin Group, commented: “The acquisition of the Electron Paramagnetic Resonance (EPR) business of Bridge12 aligns with our mission to provide cutting-edge technology to our research customers. The addition of Dr. Maly and his team will enhance our R&D capabilities in EPR for driving progress in magnetic resonance technologies.”
About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.
Media Contact:
Markus Ziegler
Sr. Director and Head of Group Marketing
Bruker BioSpin
T: +49 172 3733531
E: pr@bruker.com